Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $75 from $50 and keeps a Neutral rating on the shares following the Q3 report. The firm says PTC reported a strong first quarter of Sephience sales.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strong Market Position and Growth Potential Drive Buy Rating
- PTC Therapeutics: Balancing Sephience Success with DMD Challenges and Strategic Shifts
- PTC Therapeutics Reports Strong Q3 2025 Results
- PTC Therapeutics Reports Strong Q3 2025 Financial Results
- PTC Therapeutics reports Q3 EPS 20c, consensus ($1.11)